Roles of cancer-associated fibroblasts (CAFs) in anti- PD-1/PD-L1 immunotherapy for solid cancers
Abstract In recent years, breakthroughs have been made in tumor immunotherapy. However, tumor immunotherapy, particularly anti-PD-1/PD-L1 immune checkpoint inhibitors, is effective in only a small percentage of patients in solid cancer. How to improve the efficiency of cancer immunotherapy is an urg...
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2023-02-01
|
| Series: | Molecular Cancer |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s12943-023-01731-z |
| _version_ | 1811166080551354368 |
|---|---|
| author | Liping Pei Yang Liu Lin Liu Shuochen Gao Xueyan Gao Yudi Feng Zhenqiang Sun Yan Zhang Chengzeng Wang |
| author_facet | Liping Pei Yang Liu Lin Liu Shuochen Gao Xueyan Gao Yudi Feng Zhenqiang Sun Yan Zhang Chengzeng Wang |
| author_sort | Liping Pei |
| collection | DOAJ |
| description | Abstract In recent years, breakthroughs have been made in tumor immunotherapy. However, tumor immunotherapy, particularly anti-PD-1/PD-L1 immune checkpoint inhibitors, is effective in only a small percentage of patients in solid cancer. How to improve the efficiency of cancer immunotherapy is an urgent problem to be solved. As we all know, the state of the tumor microenvironment (TME) is an essential factor affecting the effectiveness of tumor immunotherapy, and the cancer-associated fibroblasts (CAFs) in TME have attracted much attention in recent years. As one of the main components of TME, CAFs interact with cancer cells and immune cells by secreting cytokines and vesicles, participating in ECM remodeling, and finally affecting the immune response process. With the in-depth study of CAFs heterogeneity, new strategies are provided for finding targets of combination immunotherapy and predicting immune efficacy. In this review, we focus on the role of CAFs in the solid cancer immune microenvironment, and then further elaborate on the potential mechanisms and pathways of CAFs influencing anti-PD-1/PD-L1 immunotherapy. In addition, we summarize the potential clinical application value of CAFs-related targets and markers in solid cancers. |
| first_indexed | 2024-04-10T15:46:44Z |
| format | Article |
| id | doaj.art-be2a42558d71476eafb912edd06bfb16 |
| institution | Directory Open Access Journal |
| issn | 1476-4598 |
| language | English |
| last_indexed | 2024-04-10T15:46:44Z |
| publishDate | 2023-02-01 |
| publisher | BMC |
| record_format | Article |
| series | Molecular Cancer |
| spelling | doaj.art-be2a42558d71476eafb912edd06bfb162023-02-12T12:06:03ZengBMCMolecular Cancer1476-45982023-02-0122111810.1186/s12943-023-01731-zRoles of cancer-associated fibroblasts (CAFs) in anti- PD-1/PD-L1 immunotherapy for solid cancersLiping Pei0Yang Liu1Lin Liu2Shuochen Gao3Xueyan Gao4Yudi Feng5Zhenqiang Sun6Yan Zhang7Chengzeng Wang8Department of Ultrasound, The First Affiliated Hospital of Zhengzhou UniversityDepartment of Radiotherapy, Affiliated Cancer Hospital of Zhengzhou University, Henan Cancer HospitalDepartment of Ultrasound, The First Affiliated Hospital of Zhengzhou UniversityDepartment of Neurology, The First Affiliated Hospital of Zhengzhou UniversityDepartment of Ultrasound, The First Affiliated Hospital of Zhengzhou UniversityDepartment of Ultrasound, The First Affiliated Hospital of Zhengzhou UniversityHenan Institute of Interconnected Intelligent Health Management, The First Affiliated Hospital of Zhengzhou UniversityDepartment of Ultrasound, The First Affiliated Hospital of Zhengzhou UniversityDepartment of Ultrasound, The First Affiliated Hospital of Zhengzhou UniversityAbstract In recent years, breakthroughs have been made in tumor immunotherapy. However, tumor immunotherapy, particularly anti-PD-1/PD-L1 immune checkpoint inhibitors, is effective in only a small percentage of patients in solid cancer. How to improve the efficiency of cancer immunotherapy is an urgent problem to be solved. As we all know, the state of the tumor microenvironment (TME) is an essential factor affecting the effectiveness of tumor immunotherapy, and the cancer-associated fibroblasts (CAFs) in TME have attracted much attention in recent years. As one of the main components of TME, CAFs interact with cancer cells and immune cells by secreting cytokines and vesicles, participating in ECM remodeling, and finally affecting the immune response process. With the in-depth study of CAFs heterogeneity, new strategies are provided for finding targets of combination immunotherapy and predicting immune efficacy. In this review, we focus on the role of CAFs in the solid cancer immune microenvironment, and then further elaborate on the potential mechanisms and pathways of CAFs influencing anti-PD-1/PD-L1 immunotherapy. In addition, we summarize the potential clinical application value of CAFs-related targets and markers in solid cancers.https://doi.org/10.1186/s12943-023-01731-zCancer-associated fibroblastsPD-1/PD-L1 inhibitorsImmunotherapy |
| spellingShingle | Liping Pei Yang Liu Lin Liu Shuochen Gao Xueyan Gao Yudi Feng Zhenqiang Sun Yan Zhang Chengzeng Wang Roles of cancer-associated fibroblasts (CAFs) in anti- PD-1/PD-L1 immunotherapy for solid cancers Molecular Cancer Cancer-associated fibroblasts PD-1/PD-L1 inhibitors Immunotherapy |
| title | Roles of cancer-associated fibroblasts (CAFs) in anti- PD-1/PD-L1 immunotherapy for solid cancers |
| title_full | Roles of cancer-associated fibroblasts (CAFs) in anti- PD-1/PD-L1 immunotherapy for solid cancers |
| title_fullStr | Roles of cancer-associated fibroblasts (CAFs) in anti- PD-1/PD-L1 immunotherapy for solid cancers |
| title_full_unstemmed | Roles of cancer-associated fibroblasts (CAFs) in anti- PD-1/PD-L1 immunotherapy for solid cancers |
| title_short | Roles of cancer-associated fibroblasts (CAFs) in anti- PD-1/PD-L1 immunotherapy for solid cancers |
| title_sort | roles of cancer associated fibroblasts cafs in anti pd 1 pd l1 immunotherapy for solid cancers |
| topic | Cancer-associated fibroblasts PD-1/PD-L1 inhibitors Immunotherapy |
| url | https://doi.org/10.1186/s12943-023-01731-z |
| work_keys_str_mv | AT lipingpei rolesofcancerassociatedfibroblastscafsinantipd1pdl1immunotherapyforsolidcancers AT yangliu rolesofcancerassociatedfibroblastscafsinantipd1pdl1immunotherapyforsolidcancers AT linliu rolesofcancerassociatedfibroblastscafsinantipd1pdl1immunotherapyforsolidcancers AT shuochengao rolesofcancerassociatedfibroblastscafsinantipd1pdl1immunotherapyforsolidcancers AT xueyangao rolesofcancerassociatedfibroblastscafsinantipd1pdl1immunotherapyforsolidcancers AT yudifeng rolesofcancerassociatedfibroblastscafsinantipd1pdl1immunotherapyforsolidcancers AT zhenqiangsun rolesofcancerassociatedfibroblastscafsinantipd1pdl1immunotherapyforsolidcancers AT yanzhang rolesofcancerassociatedfibroblastscafsinantipd1pdl1immunotherapyforsolidcancers AT chengzengwang rolesofcancerassociatedfibroblastscafsinantipd1pdl1immunotherapyforsolidcancers |